Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?

Susan H. Wei; Robert Brown; Tim H.M. Huang

doi:10.1111/j.1749-6632.2003.tb05979.x

Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?

Susan H. Wei, Robert Brown, Tim H.M. Huang

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

Original language	English (US)
Pages (from-to)	243-250
Number of pages	8
Journal	Annals of the New York Academy of Sciences
Volume	983
DOIs	https://doi.org/10.1111/j.1749-6632.2003.tb05979.x
State	Published - Mar 2003
Externally published	Yes

Keywords

And mismatch repair
Chemotherapy
Cisplatin
DNA methylation
Drug-resistance
High-throughput
Microarray

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
General Neuroscience
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2003.tb05979.x

Cite this

@article{839e570b995142ddad04498f06f39838,

title = "Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?",

abstract = "Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.",

keywords = "And mismatch repair, Chemotherapy, Cisplatin, DNA methylation, Drug-resistance, High-throughput, Microarray",

author = "Wei, {Susan H.} and Robert Brown and Huang, {Tim H.M.}",

year = "2003",

month = mar,

doi = "10.1111/j.1749-6632.2003.tb05979.x",

language = "English (US)",

volume = "983",

pages = "243--250",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Aberrant DNA methylation in ovarian cancer

T2 - Is there an epigenetic predisposition to drug response?

AU - Wei, Susan H.

AU - Brown, Robert

AU - Huang, Tim H.M.

PY - 2003/3

Y1 - 2003/3

N2 - Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

AB - Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

KW - And mismatch repair

KW - Chemotherapy

KW - Cisplatin

KW - DNA methylation

KW - Drug-resistance

KW - High-throughput

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=0345701519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345701519&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2003.tb05979.x

DO - 10.1111/j.1749-6632.2003.tb05979.x

M3 - Article

C2 - 12724229

AN - SCOPUS:0345701519

SN - 0077-8923

VL - 983

SP - 243

EP - 250

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this